Dean M Wingerchuk1, Moses Rodriguez. 1. Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA. wingerchuk.dean@mayo.edu
Abstract
BACKGROUND: Many women with multiple sclerosis (MS) experience transient neurologic symptom worsening and fatigue in conjunction with the menstrual cycle. Aspirin reduces MS fatigue in some patients. OBJECTIVE: To describe 3 women with MS who experienced stereotypic, temperature-independent neurologic symptoms and diurnal fatigue in the mid-to-late luteal phase of the menstrual cycle. Aspirin treatment prevented the symptoms. DESIGN AND SETTING: Case series at the Mayo Clinic outpatient MS clinics, Scottsdale, Ariz, and Rochester, Minn. PATIENTS: Three women with relapsing-remitting MS. INTERVENTIONS: Body temperature measurement, symptom diary, and oral aspirin. MAIN OUTCOME MEASURES: Body temperature, Modified Fatigue Impact Scale, and evaluation of neurologic symptoms and signs. RESULTS: Morning oral body temperature did not differ during symptomatic vs asymptomatic portions of the luteal phase (P = .55). Aspirin (650 mg twice daily) prevented symptoms but did not significantly alter the luteal phase body temperature. CONCLUSIONS: Aspirin prophylaxis may prevent luteal phase-associated MS pseudoexacerbations. However, the observed relationship between the luteal menstrual phase and MS symptom worsening is not fully explained by thermoregulation, which implicates other hormonal or immunologic mechanisms.
BACKGROUND: Many women with multiple sclerosis (MS) experience transient neurologic symptom worsening and fatigue in conjunction with the menstrual cycle. Aspirin reduces MS fatigue in some patients. OBJECTIVE: To describe 3 women with MS who experienced stereotypic, temperature-independent neurologic symptoms and diurnal fatigue in the mid-to-late luteal phase of the menstrual cycle. Aspirin treatment prevented the symptoms. DESIGN AND SETTING: Case series at the Mayo Clinic outpatient MS clinics, Scottsdale, Ariz, and Rochester, Minn. PATIENTS: Three women with relapsing-remitting MS. INTERVENTIONS: Body temperature measurement, symptom diary, and oral aspirin. MAIN OUTCOME MEASURES: Body temperature, Modified Fatigue Impact Scale, and evaluation of neurologic symptoms and signs. RESULTS: Morning oral body temperature did not differ during symptomatic vs asymptomatic portions of the luteal phase (P = .55). Aspirin (650 mg twice daily) prevented symptoms but did not significantly alter the luteal phase body temperature. CONCLUSIONS:Aspirin prophylaxis may prevent luteal phase-associated MS pseudoexacerbations. However, the observed relationship between the luteal menstrual phase and MS symptom worsening is not fully explained by thermoregulation, which implicates other hormonal or immunologic mechanisms.
Authors: Teresa C Frohman; Scott L Davis; Shin Beh; Benjamin M Greenberg; Gina Remington; Elliot M Frohman Journal: Nat Rev Neurol Date: 2013-06-04 Impact factor: 42.937
Authors: Noel G Carlson; Monica A Rojas; Jonathan W Redd; Philip Tang; Blair Wood; Kenneth E Hill; John W Rose Journal: J Neuroinflammation Date: 2010-04-13 Impact factor: 8.322
Authors: Adalia H Jun-O'connell; Nils Henninger; Majaz Moonis; Brian Silver; Carolina Ionete; Richard P Goddeau Journal: Neurohospitalist Date: 2019-02-21